Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 1405-1411

  Suh, Young Ah ^a   Jo, Se Young ^a   Lee, Hwa Young ^b   Lee, Chuhee ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

Apigenin; Axl; IL 6; Ovarian cancer; STAT3; Taxol resistance; Tyro3

Indexed keywords

APIGENIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; PROTEIN BCL XL; PROTEIN KINASE AXL; PROTEIN KINASE TYRO3; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PACLITAXEL; PROTEIN KINASE INHIBITOR; TYRO3 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOWN REGULATION; GENE SILENCING; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APIGENIN; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-6; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84921897519     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2808     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Cohen JG, White M, Cruz A and Farias-Eisner R: In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 5: 286-300, 2014.
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
4. Levy DE and Darnell JE Jr: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662, 2002.
5. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS and Huang CY: IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289: L446-L453, 2005.
6. Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557, 2000.
7. Ohashi K, Mizuno K, Kuma K, Miyata T and Nakamura T: Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene 9: 699-705, 1994.
8. Sasaki T, Knyazev PG, Clout NJ, et al: Structural basis for Gas6-Axl signalling. EMBO J 25: 80-87, 2006.
9. Stitt TN, Conn G, Gore M, et al: The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80: 661-670, 1995.
10. Hafizi S and Dahlback B: Gas6 and protein S: Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 273: 5231-5244, 2006.
11. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ and Hung MC: Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 8: 361-367, 2002.
12. Craven RJ, Xu LH, Weiner TM, et al: Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60: 791-797, 1995.
13. Wu CW, Li AF, Chi CW, et al: Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 22: 1071-1078, 2002.
14. Challier C, Uphoff CC, Janssen JW and Drexler HG: Differential expression of the ufo/axl oncogene in human leukemia-lymphoma cell lines. Leukemia 10: 781-787, 1996.
15. Gyorffy B and Lage H: A Web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol 127: 394-399, 2007.
16. De Vos J, Couderc G, Tarte K, et al: Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98: 771-780, 2001.
17. Macleod K, Mullen P, Sewell J, et al: Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 65: 6789-6800, 2005.
18. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204: 36-44, 2005.
19. Birt DF, Hendrich S and Wang W: Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90: 157-177, 2001.
20. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
21. Manach C, Scalbert A, Morand C, Remesy C and Jimenez L: Polyphenols: food sources and bioavailability. Am J Clin Nutr 79: 727-747, 2004.
22. Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21: 381-406, 2001.
23. Zheng PW, Chiang LC and Lin CC: Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci 76: 1367-1379, 2005.
24. Lu HF, Chie YJ, Yang MS, et al: Apigenin induces apoptosis in human lung cancer H460 cells through caspase- and mitochondria-dependent pathways. Hum Exp Toxicol 30: 1053-1061, 2011.
25. Zhong Y, Krisanapun C, Lee SH, et al: Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer 46: 3365-3374, 2010.
26. Ruela-de-Sousa RR, Fuhler GM, Blom N, Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis 1: e19, 2010.
27. Li ZD, Hu XW, Wang YT and Fang J: Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1. FEBS Lett 583: 1999-2003, 2009.
28. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC and Pelling JC: Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog 47: 686-700, 2008.
29. Barre B, Vigneron A, Perkins N, Roninson IB, Gamelin E and Coqueret O: The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13: 4-11, 2007.
30. McGuire WP III: Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 21 (suppl 10): 133-135, 2003.
31. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
32. Ozols RF: Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33: S3-S11, 2006.
33. Tian C, Ambrosone CB, Darcy KM, et al: Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 124: 575-581, 2012.
34. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
35. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK and Kuo ML: Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 60: 120-129, 2004.
36. Conze D, Weiss L, Regen PS, et al: Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858, 2001.
37. Wimmel A, Glitz D, Kraus A, Roeder J and Schuermann M: Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37: 2264-2274, 2001.
38. Linger RM, Keating AK, Earp HS and Graham DK: Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 14: 1073-1090, 2010.
39. Ye X, Li Y, Stawicki S, et al: An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29: 5254-5264, 2010.
40. Birt DF, Walker B, Tibbels MG and Bresnick E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis 7: 959-963, 1986.